Lahore: The Pakistan Credit Rating Agency Limited (PACRA) has assigned its initial entity ratings to BF Biosciences Limited, marking a notable development for Pakistan’s pioneering biotech formulation company. BF Biosciences, engaged in the production, marketing, and distribution of a wide array of biological and non-biological medicines, has shown significant growth and strategic partnerships that enhance its market standing.

BF Biosciences Limited, known for its life-saving medications in fields such as hepatology, cardiology, and oncology, operates a cutting-edge manufacturing facility designed by Telstar Projects. This facility adheres to stringent international standards, including those of the EU and USFDA. A collaboration with Bago Group, a prominent Argentine multinational in the pharmaceutical sector, further bolsters its product lineup.

The company’s association with its parent, Ferozsons Laboratories Limited, provides additional support. Ferozsons maintains a strong presence in the pharmaceutical industry through various strategic alliances. BF Biosciences focuses on chronic therapies, with a product mix of 60% non-biological and 40% biological medicines. Notable brands include Peg-INF and Sematide.

In the first half of the fiscal year 2025, BF Biosciences reported a revenue growth of approximately 48.3%, primarily due to increased sales volumes. The company’s gross margins saw a slight improvement, while net margins experienced a reduction. The financial profile of BF Biosciences includes moderate coverage ratios and leveraged capital structure, primarily supported by long-term debt for capital expenditures.

The sustainability of BF Biosciences’ growth and profitability, along with consistent performance indicators, will remain crucial for maintaining its ratings. The company’s ability to manage cash flows and coverages effectively is imperative for its continued success.